Vaccines and antigen presentation
LM-DC antigen-presenting cell technology
Uses an attenuated Listeria vector carrying tumour antigens to stimulate the patient’s dendritic cells outside the body for antigen presentation to T cells.
- Technology basis
- Attenuated LM vector and own DCs
- Samples and tests
- Antigen information and blood cells
- Key feature
- Ex-vivo antigen loading and presentation
Overview
LM refers to the Listeria vector and DC to dendritic cells, one type of antigen-presenting cell (APC). This approach combines an antigen-carrying vector with the patient’s DCs outside the body to support antigen presentation to T cells. Antigen-loaded DCs convey immune information to direct antigen-specific T-cell responses.
How it works
- 01
Vector carries the antigen
Select tumour-associated antigens or neoantigens and convey them through an attenuated Listeria vector.
- 02
DCs acquire and present antigens
Culture the patient’s cells, differentiate and stimulate DCs, using their antigen-processing and MHC I/II presentation functions.
- 03
Direct T-cell responses
Antigen-loaded cells support presentation, aiming to induce corresponding CD4+ and CD8+ T-cell responses.
This illustrates the mechanism. Antigen-specific immune responses do not establish clinical benefit, which requires separate evidence.
Technology approach
Two linked manufacturing paths are involved: tumour testing informs antigen selection and vector construction, while blood mononuclear cells provide monocytes for DC culture and differentiation. The paths meet during ex-vivo antigen stimulation, followed by quality tests and, where needed, freezing and thawing. The resulting product consists of autologous cells, distinct from direct administration of a vector vaccine.
DCs and macrophages both belong to the APC family. Culture processes, quality measures and functional characteristics differ, so observations must be interpreted for the specific cell type.
Samples and manufacturing process
This outlines the main technical stages. Sampling, manufacturing and quality-testing time vary with the protocol and samples.
- 01
Antigens and sample preparation
Use tumour information, necessary tests and the antigen strategy to specify vector cargo, while assessing cell collection.
- 02
Collection and DC culture
Collect PBMCs by apheresis, isolate monocytes and culture them into DCs, with maturation stimulation under the manufacturing process.
- 03
Antigen loading and quality tests
Stimulate DCs with antigen-carrying attenuated LM outside the body, then test identity, viability, count, microbiological quality and residual Listeria.
- 04
Product preparation and immune monitoring
Arrange freezing, thawing and administration as needed, monitor safety and antigen-specific T-cell responses, with separate clinical reassessment.
Samples and assessment considerations
- Clarify antigen source, pathology and molecular information, and whether further tissue testing is needed.
- Assess blood counts, infections and immune status to determine feasibility of blood-cell collection.
- Verify cell identity and batch quality records and clarify monitoring and review plans.
Monitoring and follow-up
Immune responses and observation
Monitor vital signs, blood counts, biochemistry and immune measures. Tests such as ELISpot examine specific T-cell responses, which must be interpreted separately from imaging, symptoms and overall disease status.
Quality control and safety monitoring
An attenuated vector and autologous cells still require strict quality control and safety observation. Collection-related symptoms, fever, allergy, inflammatory reactions and infection remain relevant; attenuation does not remove all risk.
Common questions
Is LM-DC a stem-cell technology?
DCs are dendritic antigen-presenting cells. The approach is not based on replacing blood stem cells or rebuilding blood formation.
Does attenuated Listeria mean direct bacterial injection?
LM-DC stimulates autologous DCs outside the body, followed by product quality testing and cell administration. This differs from direct administration of a vector vaccine.
Related programmes
Personalised mRNA neoantigen vaccine
Explore the programmePeptidePersonalised neoantigen peptide vaccine
Explore the programmeTILTIL: tumour-infiltrating lymphocytes
Explore the programmeProgramme enquiries and records
HuaCure helps organise existing records, clarify programme requirements and coordinate specialist enquiries. Explore the technology, then discuss your circumstances with the medical team.
This website provides information, not medical advice. Healthcare providers assess diagnosis, treatment suitability, risks and research eligibility. HuaCure coordinates care and does not guarantee outcomes or study enrolment.
Compiled from programme technical materials and public medical sources to explain mechanisms and processes. It is not an individual medical recommendation or a promise of benefit.
Sources
Public information checked: 7 October 2026